Evidence map›Paper›PMID 33887960›Full record

Trial reportCirculation. Genomic and precision medicine2021

Identifying the Lipidomic Effects of a Rare Loss-of-Function Deletion in

Nicholas B Blackburn, Peter J Meikle, Juan M Peralta, Satish Kumar, Ana C Leandro, Melissa A Bellinger, Corey Giles, Kevin Huynh, Michael C Mahaney, Harald H H Göring and 7 more

Open access · bronzeAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Circulation. Genomic and precision medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 2 countries.

Nicholas B BlackburnSouth Texas Diabetes and Obesity Institute (N.B.B., J.M.P., S.K., A.C.L., M.C.M., H.H.H.G., J.L.V., S.W.-B., R.D., J.B., J.E.C.), School of Medicine, The University of Texas Rio Grande Valley, Brownsville, TX.
Peter J MeikleBaker Heart and Diabetes Institute, Melbourne, VIC, Australia (P.J.M., C.G., K.H.).
Juan M PeraltaSouth Texas Diabetes and Obesity Institute (N.B.B., J.M.P., S.K., A.C.L., M.C.M., H.H.H.G., J.L.V., S.W.-B., R.D., J.B., J.E.C.), School of Medicine, The University of Texas Rio Grande Valley, Brownsville, TX.
Satish KumarSouth Texas Diabetes and Obesity Institute (N.B.B., J.M.P., S.K., A.C.L., M.C.M., H.H.H.G., J.L.V., S.W.-B., R.D., J.B., J.E.C.), School of Medicine, The University of Texas Rio Grande Valley, Brownsville, TX.
Ana C LeandroSouth Texas Diabetes and Obesity Institute (N.B.B., J.M.P., S.K., A.C.L., M.C.M., H.H.H.G., J.L.V., S.W.-B., R.D., J.B., J.E.C.), School of Medicine, The University of Texas Rio Grande Valley, Brownsville, TX.
Melissa A BellingerEli Lilly and Company, Indianapolis, IN (M.A.B., L.F.M.).
Corey GilesBaker Heart and Diabetes Institute, Melbourne, VIC, Australia (P.J.M., C.G., K.H.).
Kevin HuynhBaker Heart and Diabetes Institute, Melbourne, VIC, Australia (P.J.M., C.G., K.H.).
Michael C MahaneySouth Texas Diabetes and Obesity Institute (N.B.B., J.M.P., S.K., A.C.L., M.C.M., H.H.H.G., J.L.V., S.W.-B., R.D., J.B., J.E.C.), School of Medicine, The University of Texas Rio Grande Valley, Brownsville, TX.
Harald H H GöringSouth Texas Diabetes and Obesity Institute (N.B.B., J.M.P., S.K., A.C.L., M.C.M., H.H.H.G., J.L.V., S.W.-B., R.D., J.B., J.E.C.), School of Medicine, The University of Texas Rio Grande Valley, Brownsville, TX.
John L VandeBergSouth Texas Diabetes and Obesity Institute (N.B.B., J.M.P., S.K., A.C.L., M.C.M., H.H.H.G., J.L.V., S.W.-B., R.D., J.B., J.E.C.), School of Medicine, The University of Texas Rio Grande Valley, Brownsville, TX.
Sarah Williams-BlangeroSouth Texas Diabetes and Obesity Institute (N.B.B., J.M.P., S.K., A.C.L., M.C.M., H.H.H.G., J.L.V., S.W.-B., R.D., J.B., J.E.C.), School of Medicine, The University of Texas Rio Grande Valley, Brownsville, TX.
David C GlahnDepartment of Psychiatry, Boston Children's Hospital and Harvard Medical School, Boston, MA (D.C.G.).
Ravindranath DuggiralaSouth Texas Diabetes and Obesity Institute (N.B.B., J.M.P., S.K., A.C.L., M.C.M., H.H.H.G., J.L.V., S.W.-B., R.D., J.B., J.E.C.), School of Medicine, The University of Texas Rio Grande Valley, Brownsville, TX.
John BlangeroSouth Texas Diabetes and Obesity Institute (N.B.B., J.M.P., S.K., A.C.L., M.C.M., H.H.H.G., J.L.V., S.W.-B., R.D., J.B., J.E.C.), School of Medicine, The University of Texas Rio Grande Valley, Brownsville, TX.
Laura F Michael *Eli Lilly and Company, Indianapolis, IN (M.A.B., L.F.M.).
Joanne E Curran *South Texas Diabetes and Obesity Institute (N.B.B., J.M.P., S.K., A.C.L., M.C.M., H.H.H.G., J.L.V., S.W.-B., R.D., J.B., J.E.C.), School of Medicine, The University of Texas Rio Grande Valley, Brownsville, TX.
The University of Texas Rio Grande Valley · USBaker Heart and Diabetes Institute · AUEli Lilly (United States) · USUniversity of Tasmania · AUBoston Children's Hospital · USMACOM (United States) · US

Funding

PEDIGREE ANALYSIS OF LIPOPROTEIN PHENOTYPESP01HL045522 · NHLBI · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI ALMASY, LAURA A. · 1991 to 2012
$27.6M
Multiethnic Study of Type 2 Diabetes GenesU01DK085526 · NIDDK · BROAD INSTITUTE, INC. · PI ALTSHULER, DAVID, JABLONSKI, KATHLEEN ANN · 2009 to 2014
$15.7M
Whole Genome Sequencing to Identify Causal Genetic Variants Influencing CVD RiskR01HL113323 · NHLBI · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI BLANGERO, JOHN, CURRAN, JOANNE E. · 2012 to 2016
$8.2M
Quantitative Trait Locus Mapping in Human PedigreesR37MH059490 · NIMH · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI BLANGERO, JOHN · 2001 to 2010
$6.8M
Discovery of Functional Variants in Type 2 Diabetes Genes in Mexican AmericansU01DK085524 · NIDDK · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI BLANGERO, JOHN, DEFRONZO, RALPH A · 2009 to 2019
$5.9M
SOLAR-Eclipse Computational Tools for Imaging GeneticsR01EB015611 · NIBIB · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI KOCHUNOV, PETER V. · 2012 to 2024
$5.0M
Identifying T2D Variants by DNA Sequencing in Multiethnic SamplesU01DK085584 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ABECASIS, GONCALO, BOEHNKE, MICHAEL L · 2009 to 2013
$4.1M
Construction of a Biomedical Research Facility at the U*C06RR020547 · NCRR · UNIV/TEXAS BROWNSVILLE & SOUTHMOST COLL · PI KROUSE, JOHN H · 2010 to 2010
$4.0M
Identification of the Exposome in Fatty Liver Disease in Mexican American Families Using Genetic CorrectionR01MD012564 · NIMHD · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI BLANGERO, JOHN, CLARKE, GEOFFREY DAVID · 2018 to 2022
$3.7M
Identifying variants causal for Type 2 Diabetes in Major human populationsU01DK085545 · NIDDK · UNIVERSITY OF OXFORD · PI CHAN, JULIANA CN, EBRAHIM, SHAH BRIAN · 2009 to 2013
$2.8M
Identification and Replication of Type 2 Diabetes Genes in Mexican AmericansU01DK085501 · NIDDK · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI HANIS, CRAIG L · 2009 to 2013
$2.7M
Genetic Determinants of Lipidomic Variation and Their Role in CVD RiskR01HL140681 · NHLBI · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI CURRAN, JOANNE E., MEIKLE, PETER JOHN · 2018 to 2021
$2.4M
NCRR NIH HHS C06 RR020547NHLBI NIH HHS P01 HL045522NHLBI NIH HHS R01 HL113323NHLBI NIH HHS R01 HL140681NIBIB NIH HHS R01 EB015611NIDDK NIH HHS U01 DK085501NIDDK NIH HHS U01 DK085524NIDDK NIH HHS U01 DK085526NIDDK NIH HHS U01 DK085545NIDDK NIH HHS U01 DK085584NIMHD NIH HHS R01 MD012564NIMH NIH HHS R37 MH059490
6 · The paper itself

Abstract

backgroundThe identification and understanding of therapeutic targets for atherosclerotic cardiovascular disease is of fundamental importance given its global health and economic burden. Inhibition of ANGPTL3 (angiopoietin-like 3) has demonstrated a cardioprotective effect, showing promise for atherosclerotic cardiovascular disease treatment, and is currently the focus of ongoing clinical trials. Here, we assessed the genetic basis of variation in ANGPTL3 levels in the San Antonio Family Heart Study.

methodsWe assayed ANGPTL3 protein levels in ≈1000 Mexican Americans from extended pedigrees. By drawing upon existing plasma lipidome profiles and genomic data we conducted analyses to understand the genetic basis to variation in ANGPTL3 protein levels, and accordingly the correlation with the plasma lipidome.

resultsIn a variance components framework, we identified that variation in ANGPTL3 was significantly heritable (h

conclusionsVariation in ANGPTL3 protein levels is heritable and under significant genetic control. Both ANGPTL3 levels and loss-of-function variants in

Indexed as

Angiopoietin-Like Protein 3AtherosclerosisLoss of Function MutationMexican AmericansPhosphatidylinositolsAdultFemaleHumansLipidomicsMaleMiddle AgedAngiopoietin-Like Protein 3ANGPTL3 protein, humanPhosphatidylinositolsassociationcardiovascular diseasesgenomiclipidomicpedigreephenotype

Identifiers

PMID33887960
PMCPMC8206021
OpenAlexW3154531376

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.